The Footprint of Type 1 Diabetes on Red Blood Cells: A Metabolomic and Lipidomic Study.
Por:
Herance JR, Ciudin A, Lamas-Domingo R, Aparicio-Gómez C, Hernández C, Simó R and Palomino-Schätzlein M
Publicada:
10 ene 2023
Resumen:
The prevalence of diabetes type 1 (T1D) in the world populations is continuously growing. Although treatment methods are improving, the diagnostic is still symptom-based and sometimes far after onset of the disease. In this context, the aim of the study was the search of new biomarkers of the disease in red blood cells (RBCs), until now unexplored. The metabolomic and the lipidomic profile of RBCs from T1D patients and matched healthy controls was determined by NMR spectroscopy, and different multivariate discrimination models were built to select the metabolites and lipids that change most significantly. Relevant metabolites were further confirmed by univariate statistical analysis. Robust separation in the metabolomic and lipidomic profiles of RBCs from patients and controls was confirmed by orthogonal projection on latent structure discriminant analysis (OPLS-DA), random forest analysis, and significance analysis of metabolites (SAM). The main changes were detected in the levels of amino acids, organic acids, creatine and phosphocreatine, lipid change length, and choline derivatives, demonstrating changes in glycolysis, BCAA metabolism, and phospholipid metabolism. Our study proves that robust differences exist in the metabolic and lipidomic profile of RBCs from T1D patients, in comparison with matched healthy individuals. Some changes were similar to alterations found already in RBCs of T2D patients, but others seemed to be specific for type 1 diabetes. Thus, many of the metabolic differences found could be biomarker candidates for an earlier diagnosis or monitoring of patients with T1D.
Filiaciones:
Herance JR:
Medical Molecular Imaging Research Group, Vall d'Hebron Research Institute and Autonomous University of Barcelona, 08035 Barcelona, Spain
CIBER-bbn (ISCIII), 28040 Madrid, Spain
Ciudin A:
Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, Autonomous University of Barcelona, 08035 Barcelona, Spain
CIBERDEM (ISCIII), 28040 Madrid, Spain
:
NMR Facility, Centro de Investigación Príncipe Felipe, 46013 Valencia, Spain
Aparicio-Gómez C:
Medical Molecular Imaging Research Group, Vall d'Hebron Research Institute and Autonomous University of Barcelona, 08035 Barcelona, Spain
CIBER-bbn (ISCIII), 28040 Madrid, Spain
Hernández C:
CIBER-bbn (ISCIII), 28040 Madrid, Spain
Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, Autonomous University of Barcelona, 08035 Barcelona, Spain
Simó R:
CIBER-bbn (ISCIII), 28040 Madrid, Spain
Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, Autonomous University of Barcelona, 08035 Barcelona, Spain
:
NMR Facility, Centro de Investigación Príncipe Felipe, 46013 Valencia, Spain
ProtoQSAR SL, CEEI (Centro Europeo de Empresas Innovadoras), Parque Tecnológico de Valencia, 46980 Valencia, Spain
Green Published, gold
|